NICE does not recommend everolimus as a second treatment for people with advanced renal cell carcinoma.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their lives. Everolimus did not provide enough benefits to patients to justify its high cost, even when the special considerations were applied, so NICE did not recommend it.